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ABSTRACT
Introduction. Recombinant human erythropoietin (r-HuEPO) is used to treat symptomatic anaemia due to che-
motherapy. A new r-HuEPO, Epoetin theta (Eporatio
®), was investigated and compared to placebo and Epoetin beta
in a randomised, double-blind clinical trial in adult cancer patients receiving platinum-based chemotherapy, using a
ﬁxed weekly starting dose of 20,000 IU Epoetin theta. The primary efﬁcacy endpoint was the responder rate
(complete Hb response, Hb increase  2 g/dL).
Research Design and Methods. 223 patients were randomised to s.c. treatment for 12 weeks with either Epoetin
theta (n = 76) once per week, Epoetin beta (n = 73) three times per week or placebo (n = 74). The starting dose was
20,000 IU once weekly Epoetin theta or 450 IU/kgBW per week Epoetin beta administered in 3 equal weekly doses.
Results. In the Epoetin theta group were signiﬁcantly more responders than in the placebo group (65.8 vs. 20.3%,
P < 0.0001). Epoetin beta was also more effective than placebo (71.2 vs. 20.3%, P < 0.0001). The mean weekly dose
at the time of complete Hb response was lower in the Epoetin theta group (30,000 IU) than in the Epoetin beta
group (42,230 IU). Epoetin theta was clearly more effective than placebo.
Conclusion. This small study showed, that Epoetin theta is a safe and effective treatment of symptomatic anaemia
due to platinum-based chemotherapy in cancer patients.
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Introduction
C
ancer patients may develop anaemia as
a result of disease characteristics, chemo-
therapy or due to decreased endogenous erythro-
poietin production. Erythropoietin is the essential
growth factor required for the production of
red blood cells from late progenitor cells of the
erythroid lineage in bone marrow. Patients with
reduced or absent endogenous erythropoietin pro-
duction may need to receive exogenous erythro-
poietin as replacement therapy for the stimulation
of erythropoiesis and correction of their symptom-
atic anaemia.
Anaemia due to chemotherapy is a major
clinical problem and a typical later complication
of chemotherapy treatment. The aims of manage-
ment of this condition are to minimise the use of
blood or red cell transfusions, to eliminate symp-
toms arising from anaemia, to improve quality of
life (QoL) and to minimise secondary effects of
anaemia. Transfusion is the traditional approach to
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concerns about infection risks, and the fact that the
supply of transfusion products is limited has led
to a reduction in the use of red cell transfusions,
opening up a need for alternatives to transfusion.
Recombinant human erythropoietin has been
used in the treatment of anaemia due to chemo-
therapy for more than 20 years [1,2]. All epoetins
are structurally similar and have the same polypep-
tide receptor binding sites. However, there are
subtle differences in the glycosylation patterns of
different types of epoetins.
Epoetin theta which was developed by BioGen-
eriX AG contains recombinant human erythropoi-
etin (r-HuEPO) as the active drug substance and is
structurally similar to other recombinant epoetins.
The objective of this small study was to dem-
onstrate superiority of Epoetin theta compared
to placebo for efﬁcacy and to compare the efﬁcacy
and safety proﬁle of Epoetin theta with Epoetin
beta during the treatment period of 12 weeks in
patients with solid tumours receiving platinum-
containing chemotherapy.
Patients and Methods
Patients
A multinational, multicentre, randomised,
placebo-andactive-controlled,double-blindphase
III study was performed at 54 study centres in 10
countries. The study was conducted according to
Good Clinical Practice and the Declaration of
Helsinki (1996) and all patients signed informed
consent before any study-related activities were
performed. The study protocol, amendments,
informed consent documents and other relevant
study-related documents were reviewed and
approved by independent ethics committees of all
participating countries (Argentina, Belarus, Brazil,
Bulgaria, Croatia, India, Moldova, Romania,
Russia, Ukraine). Between October 2005 and July
2007 patients with secondary anaemia related to
platinum-containing chemotherapy participated
in the study. Male and female patients 18 years
of age with histologically or cytologically proven
diagnosis of a solid tumour were eligible for the
study if they gave written informed consent and
had anaemia caused by platinum-based chemo-
therapy deﬁned by a documented Hb concentra-
tion of 11 g/dL after the last chemotherapy prior
to inclusion. Further inclusion criteria among
others requested that the patients had at least 1
previous platinum-based chemotherapy cycle as
treatmentofthecurrentmalignancyduringthelast
4 weeks and had Eastern Cooperative Oncology
Group (ECOG) performance status 0, 1, 2 or 3.
Exclusioncriteriawerepatientswithheadandneck
tumours, uncontrolled severe hypertension and
patients receiving concomitant radiotherapy. Iron
substitution was allowed during the study.
Study Design
A total of 223 patients were randomised using
a computer-generated allocation schedule in a
1:1:1 ratio stratiﬁed by country to double blind
treatment for 12 weeks with either Epoetin theta
(n = 76), Epoetin beta (n = 73) or placebo (n = 74).
The randomisation list was generated by the
Department of Biostatistics, Merckle GmbH.
Only the person administering study medication
was unblinded. All persons assessing outcomes
were blinded. Recruitment period was 15 months
and the study ended regularly. Patients ran-
domised to Epoetin theta received a starting dose
of 20,000 IU Epoetin theta subcutaneously (s.c.)
once weekly (e.g., on Mondays) and in addition
the same volume of placebo twice weekly (e.g., on
Wednesdays and Fridays) for blinding purposes.
This starting dose was increased to 40,000 IU/
week in patients who did not have a partial
response (Hb increase of 1 g/dL) after 4 weeks of
treatment, and again to 60,000 IU/week in case
of insufﬁcient response after the second 4 week
period of treatment. If the patient’s Hb level
increased by more than 2 g/dL in a 4-week period
the weekly dose was reduced by 50%. If the Hb
level exceeded 13 g/dL the dose was reduced to
50% of the recent dose or was temporarily with-
hold. Selection of the Epoetin theta doses was
based on recent evidence that lower doses than
those recommended for authorised products may
achieve comparable Hb response, that the same
weekly doses administered once or three times
weekly result in the same Hb response [3–5] and
that ﬁxed doses rather than weight-based doses
can be used in anaemic cancer patients [6]. Patients
randomised to Epoetin beta (NeoRecormon
®,
Roche Ltd., United Kingdom) received in accor-
dance with the European product information a
starting dose of 450 IU/kgBW per week s.c., admin-
istered in 3 equal doses. The dose was doubled
to 900 IU/kgBW per week in patients who did not
have a partial response after 4 weeks of treatment
(Figure 1). As this represents the maximal weekly
dose, a second dose increase was not foreseen.
Dose reductions took place according to the same
schedule as for Epoetin theta. Patients randomised
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dose adjustment according to the same schedule as
for Epoetin theta for blinding purposes.
Hb, haematocrit and reticulocytes were mea-
sured weekly throughout the study. Baseline
levels were deﬁned as the mean of two values mea-
sured prior to initiation of drug treatment. The
FACT-An questionnaire including FACT-G and
-F [7] was used to assess the QoL.
Immunogenicity was assessed by a predeﬁned
cascade of antibody assays. Conﬁrmed positive
samples were investigated for neutralising anti-
bodies in a cellular assay using an erythropoietin
dependent UT-7 cell line.
Epoetin theta and Epoetin beta were provided
in different containers and the dosing scheme was
different between Epoetin theta and Epoetin
beta. Therefore, the study drug was prepared and
administered by qualiﬁed unblinded study person-
nel who were not involved in any other study
assessments. The investigator and all other study
personnel were kept blinded and performed all
assessments of the patient without knowledge of
treatment. An unblinded, independent Data Safety
Monitoring Committee closely monitored the
safety in order to ensure that patients were not
exposed to an unjustiﬁable risk.
Endpoints
The pre-speciﬁed primary endpoint was the
number of patients with a complete Hb response
which was deﬁned as an increase in Hb of 2 g/dL
from baseline without the beneﬁt of a transfusion
within the previous four weeks. Secondary efﬁcacy
endpoints included the number of patients having
a partial Hb response (deﬁned as increase of
1 g/dL from baseline), the number of patients
having a complete Hb response with the initial
dose, the number of patients receiving transfu-
sions, the number of blood units transfused, the
time course of Hb, haematocrit and reticulocytes,
the QoL (FACT-An, including FACT-G and -F
[7]), and the dose of Epoetin theta or Epoetin beta
at the time of complete/partial Hb response. Blood
transfusions were administered on a case by case
basis at the discretion of the investigator. Transfu-
sions should have been avoided at a haemoglobin
level 8.5 g/dL. Safety endpoints included safety
lab, vital signs, incidence of adverse events (AEs)
and adverse drug reactions (ADRs), overall toler-
ability and screening for anti-drug antibodies to
Epoetin theta and Epoetin beta at the beginning
and end of the study and 60 days after the end of
the individual treatment period.
Statistical Methods
A logistic regression analysis with treatment and
baseline haemoglobin value as explanatory vari-
ables was performed to estimate the difference
in the proportion of complete haemoglobin
responders between Epoetin theta and placebo in
the conﬁrmatory analysis of the primary efﬁcacy
endpoint. The differences between Epoetin beta
and placebo and between Epoetin beta and
Epoetin theta were estimated with the same sta-
tistical model. For the other binary secondary
Figure 1 Dose adaptation of Epoetin theta and Epoetin beta.
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model as for the primary endpoint was estimated,
changes of QoL (FACT-scores) from baseline to
end of study were compared pairwise among
treatment groups with the Wilcoxon-Mann-
Whitney test, whereas the treatment groups for
the other secondary efﬁcacy endpoints were only
compared descriptively. All descriptive tables were
displayed by country; no special subgroup analysis
was performed.
The sample size calculation required the inclu-
sion of 72 patients per treatment group to achieve
a power between 90 and 95% for the statistical
superiority test comparing Epoetin theta and
placebo (two-sided a=5%) assuming the actual
response rates for Epoetin theta and placebo were
50% and 20% respectively.
Results
The demographic and baseline characteristics of
the 3 treatment groups were comparable. There
were no relevant differences between treatment
groups with regard to medical history, prior or
concomitant medications, ECOG performance
status, blood transfusions prior to study entry,
concomitant diseases, tumour types and on-study
chemotherapies (Table 1). One hundred and
eighty-one (81.2%) patients completed the study
according to protocol (Figure 2). Of the 42
patients who prematurely discontinued the study,
21 were in the placebo group, 12 were in the
Epoetin theta group and 9 were in the Epoetin
beta group. The most common reason for discon-
tinuation was patient’s request (21 patients), fol-
lowed by other (unspeciﬁed) reasons (8 patients),
AEs (7 patients) and, lost to follow-up (5 patients).
The results of efﬁcacy endpoints for the full
analysis set are summarised in Table 2 (number of
patients with a complete and partial Hb response
without blood transfusion, number of patients
with a complete Hb response without blood trans-
fusion and with the initial dose, number of patients
receiving blood transfusions and number of blood
units transfused) and Figure 3 (time course of
Hb).
Extent of Exposure
Themean  SDaverageweeklydosewashigherin
the Epoetin beta group compared to the Epoetin
theta group (36,973  13,967 vs. 26,425 
9,157 IU). This was to be expected as the weekly
starting dose of Epoetin beta was 450 IU/kgBW. For
a patient with a body weight of 69 kg (the mean
weight in the Epoetin beta group) the resulting
weekly starting dose was 31,050 IU compared to
Table 1 Patient characteristics
Epoetin theta (n = 76) Epoetin beta (n = 73) Placebo (n = 74) Total (n = 223)
Gender [n (%)]
Male 30 (39.5%) 22 (30.1%) 19 (25.7%) 71 (31.8%)
Female 46 (60.5%) 51 (69.9%) 55 (74.3%) 152 (68.2%)
Age [years]
Mean  SD 53.7  10.3 57.3  10.5 57.3  11.5 56.0  10.9
Median 53.5 57.0 59.5 57.0
Range 19.0 to 76.0 28.0 to 83.0 26.0 to 76.0 19.0 to 83.0
Body weight [kg]
Mean  SD 66.1  13.2 69.0  14.6 63.0  12.8 66.0  13.7
Median 64.5 66.6 62.1 64.0
Range 35.0 to 97.0 39.0 to 108.7 44.5 to 108.0 35.0 to 108.7
ECOG performance status
0 6 (7.9%) 9 (12.3%) 5 (6.8%) 20 (9.0%)
1 55 (72.4%) 40 (54.8%) 48 (64.9%) 143 (64.1%)
2 15 (19.7%) 24 (32.9%) 20 (27.0%) 59 (26.5%)
3 0 0 1 (1.4%) 1 (0.4%)
Most common tumour types
Ovarian epithelial cancer 14 (18.4%) 21 (28.8%) 20 (27.0%) 55 (24.7%)
Gastric cancer 6 (7.9%) 5 (6.8%) 7 (9.5%) 18 (8.1%)
Lung squamous cell carcinoma 4 (5.3%) 5 (6.8%) 7 (9.5%) 16 (7.2%)
Breast cancer 6 (7.9%) 3 (4.1%) 6 (8.1%) 15 (6.7%)
Ovarian epithelial cancer metastatic 6 (7.9%) 6 (8.2%) 3 (4.1%) 15 (6.7%)
Most common on-study CT
Cisplatin 55 (72.4%) 48 (65.8%) 42 (56.8%) 145 (65.0%)
Carboplatin 22 (28.9%) 29 (39.7%) 24 (32.4%) 75 (33.6%)
Cyclophosphamide 18 (23.7%) 17 (23.3%) 15 (20.3%) 50 (22.4%)
Etoposide 20 (26.3%) 11 (15.1%) 14 (18.9%) 45 (20.2%)
Abbreviations: n = number of patients; SD = standard deviation; CT = chemotherapy.
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transfusion, number of patients with a complete Hb response without blood transfusion and with the initial dose and
number of patients receiving blood transfusions for the full analysis set
Epoetin theta
(n = 76)
Epoetin beta
(n = 73)
Placebo
(n = 74)
Baseline Hb [g/dL] mean  standard deviation 9.6  1.1 9.5  0.8 9.4  1.2
Complete Hb response without blood transfusion [n (%)] 50 (65.8%) 52 (71.2%) 15 (20.3%)
Treatment (Epoetin theta vs. placebo)
P value <0.0001
Odds ratio (95% CI) 8.06 (3.89, 17.63)
Treatment (Epoetin beta vs. placebo)
P value <0.0001
Odds ratio (95% CI) 10.25 (4.86, 22.83)
Complete Hb response without blood transfusion and
dose adjustment [n (%)]
26 (34.2%) 29 (39.7%) 8 (10.8%)
Treatment (Epoetin theta vs. placebo)
P value 0.0012
Odds ratio (95% CI) 4.24 (1.84, 10.76)
Treatment (Epoetin beta vs. placebo)
P value 0.0001
Odds ratio (95% CI) 5.40 (2.35, 13.68)
Partial Hb response without blood transfusion [n (%)] 69 (90.8%) 66 (90.4%) 37 (50%)
Treatment (Epoetin theta vs. placebo)
P value <0.0001
Odds ratio (95% CI) 9.80 (4.19, 26.00)
Treatment (Epoetin beta vs. placebo)
P value <0.0001
Odds ratio (95% CI) 9.39 (4.01, 24.93)
Patients received blood transfusions [n (%)] 8 (10.5%) 9 (12.3%) 18 (24.3%)
Treatment (Epoetin theta vs. placebo)
P value 0.0433
Odds ratio (95% CI) 0.38 (0.14, 0.95)
Treatment (Epoetin beta vs. placebo)
P value 0.1042 (n. s.)
Abbreviations: n = number of patients; Hb = haemoglobin; CI = conﬁdence interval; n. s. = not signiﬁcant.
Figure 2 Disposition of patients.
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treated with Epoetin theta. The mean treatment
duration  SD was comparable in all 3 groups
(75.0  16.9 days Epoetin theta vs. 71.0  19.7
days Epoetin beta vs. 70.5  23.7 days placebo).
Complete Haemoglobin Response without
BloodTransfusion
The primary parameter for the conﬁrmatory
analysis was the complete Hb response (increase of
2 g/dL from baseline) without blood transfusion.
The responder rate in the Epoetin theta group
was substantially higher than in the placebo group
(65.8 vs. 20.3%). The difference between the
Epoetin theta and placebo was statistically signiﬁ-
cant (P < 0.0001) with a baseline Hb adjusted odds
ratio of 8.06 (95% CI: 3.89, 17.63).
The exploratory analysis for the other group
comparisons showed a higher responder rate in
the Epoetin beta group vs. the placebo group
(71.2 vs. 20.3%, P < 0.0001) with a baseline
Hb adjusted odds ratio of 10.25 (95% CI:
4.86, 22.83). The difference in treatment effect
between Epoetin theta and Epoetin beta was not
statistically signiﬁcant (P = 0.5004) with a base-
line Hb adjusted odds ratio of 0.79 (95%
CI: 0.39, 1.58). Baseline Hb levels had no statis-
tically signiﬁcant effects on the response rate
(P = 0.1408).
The proportion of patients who had a complete
haemoglobin response without changing the start-
ing dose was signiﬁcantly higher (P = 0.0012; OR:
4.24, 95% CI: 1.84, 10.76) in the Epoetin theta
group than in the placebo group (34.2 vs. 10.8%)
and was also signiﬁcantly higher (P = 0.0001; OR:
5.40, 95% CI: 2.35, 13.68) in the Epoetin beta
group compared to placebo (39.7 vs. 10.8%). The
difference between Epoetin theta and Epoetin beta
was not statistically signiﬁcant (P = 0.4765; OR:
0.79, 95% CI: 0.40, 1.53).
Partial Haemoglobin Response without
BloodTransfusion
The partial Hb response was deﬁned as increase of
1 g/dL from baseline without blood transfusion
within the last four week. As for the complete
Hb response, the responder rate was higher with
Epoetin theta than with placebo (90.8 vs. 50%,
P < 0.0001, OR: 9.80, 95% CI: 4.19, 26.00)
and also higher with Epoetin beta than with
placebo (90.4 vs. 50%, P < 0.0001, OR: 9.39, 95%
CI: 4.01, 24.93). The difference between Epoetin
theta and Epoetin beta was not statistically signiﬁ-
cant (P = 0.9394, OR: 1.04, 95% CI: 0.34, 3.20).
Baseline Hb levels also had no statistically signiﬁ-
cant effects on this response rate.
Number of Patients Receiving BloodTransfusions
More patients in the placebo group than in the
Epoetin theta group received blood transfusions
(24.3 vs. 10.5%, P = 0.0433, OR: 0.38, 95% CI:
0.14, 0.95). The proportion of patients receiving
blood transfusions in the Epoetin beta group was
also lower than in the placebo group (12.3 vs.
24.3%), however this difference was not statisti-
cally signiﬁcant (P = 0.1042, OR: 0.47, 95% CI:
0.18, 1.15). Baseline Hb levels had a statistically
signiﬁcant effect on the rate of blood transfusion
(P = 0.0005) with an odds ratio of 0.53 (95% CI:
0.37, 0.75) per g/dL baseline Hb comparing
Epoetin theta with placebo.
Number of Blood UnitsTransfused
The mean  SD number of blood units transfused
after randomisation in those patients who needed a
transfusion was 1.8  0.7 units in the Epoetin beta
Figure 3 Time course of mean
(SEM) haemoglobin values. Time
course of mean (SEM) haemoglobin
values for the full analysis set. Epoetin
theta (orange), Epoetin beta (blue) and
placebo (green).
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3.3  2.2 units in the Epoetin theta group.
Time Course of Haemoglobin, Haematocrit
and Reticulocytes
Baseline Hb values were similar in all 3 treatment
groups (Figure 3). Over the course of the study
mean Hb levels rose steadily in the Epoetin theta
and Epoetin beta groups, reaching 10 g/dL by day
15 in the Epoetin theta group and by day 22 in the
Epoetin beta group. In the Epoetin theta group,
mean  SD Hb levels rose from 9.6  1.1 g/dL at
baseline to 11.2  1.6 g/dL at the end of the study,
an increase of 1.6 g/dL. In the Epoetin beta group,
mean  SD Hb levels rose from 9.5  0.8 g/dL at
baseline to 11.4  2.0 g/dL at the end of the study,
an increase of 1.9 g/dL. In the placebo group,
there was no consistent change in Hb levels over
the course of the study and the mean level never
reached 10 g/dL. Mean  SD Hb levels were
9.4  1.2 g/dL at baseline and 9.6  2.0 g/dL at
the end of the study.
The changes of haematocrit values were very
similar to the changes of Hb values over time.
Absolute reticulocyte values showed a high degree
of variability in all 3 treatment groups and at all
timepoints.
Dose of EpoetinTheta or Epoetin Beta at theTime
of Partial or Complete Haemoglobin Response
The mean  SD weekly dose of Epoetin theta
at the time of complete Hb response was
30,000  12,936 IU, and at the time of partial
Hb response it was 27,826  12,469 IU. A dose
of up to 20,000 IU was sufﬁcient for complete
Hb response in 52% of patients with complete
response in the Epoetin theta dose group. A dose
of between 20,000 and 40,000 IU of Epoetin theta
was sufﬁcient to achieve complete Hb response in
a further 40% of patients with complete response.
The mean  SD weekly dose of Epoetin beta
at the time of complete Hb response was
42,230  23,455 IU, and at the time of partial
Hb response it was 39,827  21,831 IU. In the
Epoetin beta group 55.8% of patients with com-
plete response achieved this with the starting dose.
Safety Evaluation
The overall frequencies of adverse events (AEs)
were 76.3% in the Epoetin theta group, 85.1% in
the placebo group, and 86.3% in the Epoetin beta
group, see Table 3. The high incidence of AEs was
to be expected in cancer patients receiving chemo-
therapy. The overall proﬁle of the most frequently
reported AEs can be expected in the rather elderly
study population of cancer patients receiving
platinum-based chemotherapy. Frequencies only
exceeded 10% for nausea (33.2%), neutropoenia
(22.9%), asthenia (22.4%), vomiting (18.4%),
thrombocytopenia (16.6%) and leukopenia
(16.1%). The incidence of skin reactions that
might have been caused by the subcutaneous
administration of study medication was low and
comparable in all groups: 3 in Epoetin beta
patients and 1, each, in placebo and Epoetin theta
patients. The incidence of hypertension was 2.6%
in the Epoetin theta group and 2.7% in each of the
other two treatment groups.
Adverse drug reactions (ADRs) with a causal
relationship to the study medication as assessed
by the investigator were reported in 14 (18.4%)
patients in the Epoetin theta group, 13 (17.6%)
patients in the placebo group, and 16
(21.9%) patients in the Epoetin beta group. The
most common ADRs were nausea (8.5%), asthenia
(5.8%), vomiting (4.5%) and headache (3.6%). All
of these events commonly occur in cancer patients
receiving platinum-based chemotherapy.
Twenty-one of the patients in this study (5
Epoetin theta, 12 placebo, 4 Epoetin beta) died
during the study period. The most frequent reason
for death was disease progression (1 Epoetin beta,
6 placebo, 3 Epoetin theta). Serious adverse events
(SAEs) were reported in 33 (14.8%) patients (9
Epoetin theta, 15 placebo, 9 Epoetin beta). AEs
Table 3 Frequencies of TEAE categories (full analysis set)
Category of TEAE
Epoetin theta (n = 76) Epoetin beta (n = 73) Placebo (n = 74)
n% n% n%
Any TEAE 58 76.3 63 86.3 63 85.1
Related TEAE = TEADR 14 18.4 16 21.9 13 17.6
Serious TEAE 9 11.8 9 12.3 15 20.3
Serious TEADR 1 1.3 1 1.4 0 -
Death 5 6.6 4 5.5 12 16.2
Abbreviations: n = number of patients; multiple mentions per patient are possible.
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in 13 patients (4 Epoetin theta, 6 placebo, 3
Epoetin beta).
Results for safety lab variables, vital signs,
body weight, 12-lead ECG, physical examination,
tolerability, skin irritation, and results of current
chemotherapy did not give rise to any safety
concerns.
Tolerability as assessed by the patients was
very good or good in 89.3%, 76.4%, and 90.3% of
patients in the Epoetin theta, placebo, and Epoetin
beta group. Tolerability as assessed by the investi-
gators was very good or good in 93.3%, 88.9%,
and 93.1% of patients, respectively.
Response rates (complete plus partial response)
to chemotherapy were comparable in the Epoetin
theta and placebo groups (31.6% vs. 29.7%),
therefore there is no evidence that Epoetin theta
could have had a negative impact on the course of
the disease.
The incidence of anti-drug antibodies to
Epoetin theta and Epoetin beta was assessed at the
beginning and end of the study and 60 days after
the end of the individual treatment period. None
of the patients enclosed in the study developed
neutralising anti-epoetin antibodies to Epoetin
theta or Epoetin beta.
Discussion
The selection of the weekly ﬁxed starting dose of
20,000 IU Epoetin theta, which is lower than the
recommended starting dose of other epoetins, is
in line with recent recommendations for the treat-
ment of cancer patients with epoetins, i.e., to use
the lowest dose needed to avoid red blood cell
transfusion [8].
A meta-analysis based on 14 randomised
controlled trials including 2,347 cancer patients,
with haematologic response to treatment with
erythropoietin deﬁned as an increase in Hb of
at least 2 g/dL unrelated to transfusion, reported
response rates of 9–70% [9]. The corresponding
relative risk (RR) for haematologic response in the
erythropoietin group was 3.60 (95% CI: 3.07,
4.23). Thus, patients receiving an erythropoietin
are 3 to 4 times more likely to achieve Hb
response. The response rates of 65.8% in the
Epoetin theta group and 20.3% in the placebo
group observed in this study therefore compare
favourably with the literature, although the weekly
starting dose was ﬁxed and not body weight
adjusted and lower than the weekly dose in the
studies included in the above meta-analysis.
A meta-analysis based on 25 randomised
controlled trials including 3,069 cancer patients
showed that the use of erythropoietin signiﬁcantly
reduced the relative risk of red blood cell transfu-
sion (RR 0.67, 95% CI: 0.62, 0.73) [9]. The results
of the present study compare favourably with
information derived from the literature. This
holds true also for the further efﬁcacy parameters
like the haemoglobin and haematocrit levels over
time. Of note, the mean weekly dose at the time
of complete Hb response was substantially lower
in the Epoetin theta group (30,000 IU) than in the
Epoetin beta group (42,230 IU) and 52% of the
complete responders in the Epoetin beta group
achieved the response with the starting dose of
20,000 IU. This result conﬁrms that the Epoetin
theta dosing schedule tested here is suitable for an
effective and well tolerated treatment of anaemic
cancer patients.
The frequencies and type of AEs as observed in
this study were to be expected in cancer patients
receiving chemotherapy. The results indicate that
Epoetin theta generally showed a good tolerability
with an AE or ADR incidence not higher than in
the placebo group.
The number of fatalities was highest in the
placebo group in this study. Furthermore no anti-
drug antibodies to Epoetin theta and Epoetin beta
were detected in any patient of this study.
Results for other safety parameters like SAEs,
AEs leading to discontinuation, safety lab vari-
ables, vital signs, etc. did not give rise to any safety
concerns.
It should be taken into consideration that the
relatively small number of patients per treatment
group was not enough to detect rare adverse
events. For a detailed assessment of safety, further
patients would be needed.
Conclusions
In this small study, Epoetin theta with a weekly
starting dose of 20,000 IU is superior to placebo in
terms of complete Hb response without blood
transfusion. Epoetin theta is a safe and effective
treatment for the treatment of anaemia due to
platinum-based chemotherapy in patients with
solid tumours.
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